Assessing 4E-BP3 protein levels in cancers with different 4E-BP1 amounts could further address a recent study demonstrating that lower 4E-BP1 expression is associated with hightened sensitivity to the phosphoinositol 3-kinase/mTOR-targeting drugs in prostate cancer48. This evidence concerns the gene MTOR and cancer.